Here we demonstrate that clinically relevant exposure to epigenetic therapeutic agents targeting HDAC1 reverses the immune evasion phenotype of prostate and breast carcinoma cells to antigen-specific lysis by cytotoxic T cells. The gene discussed is HDAC1; the disease is breast carcinoma.